Leveraging Saliva for Insights into Head and Neck Cancer

Int J Mol Sci. 2024 Dec 17;25(24):13514. doi: 10.3390/ijms252413514.

Abstract

Head and neck cancer (HNC) represents a heterogeneous group of malignancies with increasing global incidence and notable mortality. Early detection is essential for improving survival rates and minimizing recurrence; however, existing diagnostic methods are often invasive and complex. There is a need for noninvasive and more effective approaches for early detection and real-time monitoring of HNC. Saliva contains various biomolecules that may serve as indicators of HNC. As a result, saliva-based biomarkers have emerged as a transformative approach in the diagnosis and treatment of HNC due to their ease of collection, non-invasiveness, and potential to provide details about biomolecular changes associated with cancer progression. This narrative review synthesizes the current literature on the potential of saliva as a noninvasive diagnostic tool for HNC. It highlights various biomarkers found in saliva, including cell-free DNA, RNA, proteins, and metabolites, and explores emerging technologies in saliva detection that could transform the future of HNC management. Continued research efforts and larger-scale validation studies are essential to fully realize the potential of saliva-based biopsy and help pinpoint notable biomarkers to improve patient outcomes and reduce mortality associated with HNC worldwide.

Keywords: biomarkers; biopsy; diagnosis; head and neck cancer; saliva.

Publication types

  • Review

MeSH terms

  • Biomarkers, Tumor* / metabolism
  • Cell-Free Nucleic Acids
  • Early Detection of Cancer / methods
  • Head and Neck Neoplasms* / diagnosis
  • Head and Neck Neoplasms* / metabolism
  • Head and Neck Neoplasms* / pathology
  • Humans
  • Liquid Biopsy / methods
  • Saliva* / chemistry
  • Saliva* / metabolism

Substances

  • Biomarkers, Tumor
  • Cell-Free Nucleic Acids

Grants and funding

This work was partially supported by the Winship Invest$ Team Science Award and the Winship Invest$ Pilot Award under award number P30CA138292. YT is the inaugural recipient of the Wally Award from the Winship Cancer Institute.